<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Carbenicillin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00578</strong>&#160; (APRD00846)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00578/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00578/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00578.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00578.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00578.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00578.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00578.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00578">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Carbenicilina</td><td>Spanish</td><td>INN</td></tr><tr><td>Carbenicillin</td><td>German</td><td>INN</td></tr><tr><td>Carbenicilline</td><td>French</td><td>INN</td></tr><tr><td>Carbenicillinum</td><td>Latin</td><td>INN</td></tr><tr><td>Carboxybenzylpenicillin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Carbenicillin</td><td>Polfa Tarchomin</td></tr><tr><td>Pyopen</td><td>GlaxoSmithKline</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-bacterial-agents">Anti-Bacterial Agents</a></li>
<li><a href="/mesh/penicillins">Penicillins</a></li></ul></td></tr><tr><th>CAS number</th><td>4697-36-3</td></tr><tr><th>Weight</th><td>Average: 378.4<br>Monoisotopic: 378.088557008</td></tr><tr><th>Chemical Formula</th><td>C<sub>17</sub>H<sub>18</sub>N<sub>2</sub>O<sub>6</sub>S</td></tr><tr><th>InChI Key</th><td>FPPNZSSZRUTDAP-UWFZAAFLSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C17H18N2O6S/c1-17(2)11(16(24)25)19-13(21)10(14(19)26-17)18-12(20)9(15(22)23)8-6-4-3-5-7-8/h3-7,9-11,14H,1-2H3,(H,18,20)(H,22,23)(H,24,25)/t9?,10-,11+,14-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(2S,5R,6R)-6-(2-carboxy-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C(C(O)=O)C1=CC=CC=C1)C(O)=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Lactams</td></tr><tr><th>Subclass</th><td>Beta Lactams</td></tr><tr><th>Direct parent</th><td>Penicillins</td></tr><tr><th>Alternative parents</th><td>N-acyl-alpha Amino Acids and Derivatives; Phenylacetic Acid Derivatives; Phenylpropylamines; Dicarboxylic Acids and Derivatives; Thiazolidines; Tertiary Carboxylic Acid Amides; Polyols; Azetidines; Secondary Carboxylic Acid Amides; Tertiary Amines; Hemiaminals; Thioethers; Enolates; Carboxylic Acids; Polyamines; Aminals</td></tr><tr><th>Substituents</th><td>n-acyl-alpha amino acid or derivative; phenylacetate; phenylpropylamine; benzene; dicarboxylic acid derivative; tertiary carboxylic acid amide; thiazolidine; tertiary amine; polyol; carboxamide group; azetidine; secondary carboxylic acid amide; hemiaminal; aminal; polyamine; thioether; carboxylic acid derivative; carboxylic acid; enolate; amine; alcohol; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the penicillins. These are organic compounds containing the penicillin core structure, which is structurally characterized by a penam ring bearing two methyl groups at position 2, and an amide group at position 6 [starting from the sulfur atom at position 1].</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of acute and chronic infections of the upper and lower urinary tract and in asymptomatic bacteriuria due to susceptible strains of bacteria.</td></tr><tr><th>Pharmacodynamics</th><td>Carbenicillin is a semisynthetic penicillin. Though carbenicillin provides substantial <i>in vitro</i> activity against a variety of both gram-positive and gram-negative microorganisms, the most important aspect of its profile is in its antipseudomonal and antiproteal activity. Because of the high urine levels obtained following administration, carbenicillin has demonstrated clinical efficacy in urinary infections due to susceptible strains of: <i>Escherichia coli</i>, <i>Proteus mirabilis</i>, <i>Proteus vulgaris</i>, <i>Morganella morganii</i>, <i>Pseudomonas</i> species, <i>Providencia rettgeri</i>, <i>Enterobacter</i> species, and <i>Enterococci</i> (<i>S. faecalis</i>).</td></tr><tr><th>Mechanism of action</th><td>Free carbenicillin is the predominant pharmacologically active fraction of the salt. Carbenicillin exerts its antibacterial activity by interference with final cell wall synthesis of susceptible bacteria. Penicillins acylate the penicillin-sensitive transpeptidase C-terminal domain by opening the lactam ring. This inactivation of the enzyme prevents the formation of a cross-link of two linear peptidoglycan strands, inhibiting the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that carbenicillin interferes with an autolysin inhibitor.</td></tr><tr><th>Absorption</th><td>Rapidly absorbed from the small intestine following oral administration. Oral bioavailability is 30 to 40%.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>30 to 60%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Minimal.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>1 hour</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Carbenicillin blood levels achievable are very low, and toxic reactions as a function of overdosage should not occur systematically. The oral LD<sub>50</sub> in mice is 3,600 mg/kg, in rats 2,000 mg/kg, and in dogs is in excess of 500 mg/kg. The lethal human dose is not known. Symptoms of overdose include diarrhea, nausea, stomach upset, and vomiting.</td></tr><tr><th>Affected organisms</th><td><ul><li>Enteric bacteria and other eubacteria</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              -
        </td>
        <td>0.9112</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9954</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.7812</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5274</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9447</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9872</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.962</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7684</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8611</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5946</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8778</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9259</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.935</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9206</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8921</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9761</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8884
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.6178
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.976
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.4599 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9997
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9091
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Roerig div pfizer inc</li>
<li>Glaxosmithkline</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.pfizer.com">Pfizer Inc.</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet, film coated</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00618">Demeclocycline</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00254">Doxycycline</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01357">Mestranol</a></td><td>This anti-infectious agent could decreases the effect of the oral contraceptive</td></tr><tr><td><a href="/drugs/DB00931">Methacycline</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00563">Methotrexate</a></td><td>The penicillin increases the effect and toxicity of methotrexate</td></tr><tr><td><a href="/drugs/DB01017">Minocycline</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00595">Oxytetracycline</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01301">Rolitetracycline</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00759">Tetracycline</a></td><td>Possible antagonism of action</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take on an empty stomach.</li></ul></td></tr></tbody></table>